Krause Kevin Michael 4
4 · AN2 Therapeutics, Inc. · Filed Jan 4, 2024
Insider Transaction Report
Form 4
Krause Kevin Michael
Chief Strategy Officer
Transactions
- Sale
Common Stock
2024-01-02$20.12/sh−2,583$51,967→ 1,914 total - Exercise/Conversion
Stock Option (right to buy)
2024-01-02−2,583→ 52,285 totalExercise: $0.42Exp: 2030-01-22→ Common Stock (2,583 underlying) - Exercise/Conversion
Common Stock
2024-01-02$0.42/sh+2,583$1,085→ 4,497 total
Footnotes (5)
- [F1]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2023.
- [F2]Reflects the adjusted total which includes the purchase of 934 shares under the AN2 Employee Stock Purchase Plan on March 31, 2023.
- [F3]Reflects the adjusted total which includes the purchase of 980 shares under the AN2 Employee Stock Purchase Plan on September 29, 2023.
- [F4]Price reported is a weighted-average sales price. The shares were sold at prices ranging from $20.00 to $20.26. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- [F5]The option is subject to an early exercise provision and is immediately exercisable. The shares subject to the option vest as follows: 25% of the shares vested on November 21, 2020; and 1/48th of the shares vests monthly thereafter over the following three years, subject to the Reporting Person's continuous service as of such date.